Zhejiang Medicine Future Growth
Future criteria checks 3/6
Zhejiang Medicine is forecast to grow earnings and revenue by 25.1% and 9.9% per annum respectively. EPS is expected to grow by 24.9% per annum. Return on equity is forecast to be 8.7% in 3 years.
Key information
25.1%
Earnings growth rate
24.9%
EPS growth rate
Pharmaceuticals earnings growth | 17.8% |
Revenue growth rate | 9.9% |
Future return on equity | 8.7% |
Analyst coverage | Low |
Last updated | 22 Aug 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 10,726 | 1,046 | N/A | 737 | 2 |
12/31/2025 | 9,976 | 991 | N/A | 1,750 | 3 |
12/31/2024 | 9,215 | 866 | N/A | 386 | 3 |
6/30/2024 | 8,262 | 473 | -66 | 591 | N/A |
3/31/2024 | 8,035 | 426 | -109 | 638 | N/A |
12/31/2023 | 7,794 | 430 | -163 | 634 | N/A |
9/30/2023 | 7,868 | 356 | -127 | 790 | N/A |
6/30/2023 | 7,936 | 421 | -121 | 781 | N/A |
3/31/2023 | 7,940 | 393 | -134 | 718 | N/A |
12/31/2022 | 8,116 | 540 | -455 | 521 | N/A |
9/30/2022 | 8,441 | 779 | -115 | 825 | N/A |
6/30/2022 | 8,629 | 928 | -320 | 670 | N/A |
3/31/2022 | 8,913 | 1,039 | -186 | 919 | N/A |
12/31/2021 | 9,129 | 1,045 | 197 | 1,137 | N/A |
9/30/2021 | 8,709 | 847 | 105 | 965 | N/A |
6/30/2021 | 8,416 | 798 | 402 | 1,209 | N/A |
3/31/2021 | 8,127 | 836 | 522 | 1,123 | N/A |
12/31/2020 | 7,327 | 717 | 721 | 1,257 | N/A |
9/30/2020 | 7,154 | 603 | 201 | 853 | N/A |
6/30/2020 | 6,987 | 489 | 234 | 782 | N/A |
3/31/2020 | 6,925 | 358 | 67 | 657 | N/A |
12/31/2019 | 7,044 | 343 | -126 | 447 | N/A |
9/30/2019 | 7,073 | 210 | 116 | 496 | N/A |
6/30/2019 | 7,052 | 177 | 111 | 555 | N/A |
3/31/2019 | 6,655 | 32 | 288 | 693 | N/A |
12/31/2018 | 6,859 | 365 | 141 | 580 | N/A |
9/30/2018 | 6,879 | 636 | 225 | 652 | N/A |
6/30/2018 | 6,600 | 632 | 55 | 504 | N/A |
3/31/2018 | 6,426 | 694 | N/A | 335 | N/A |
12/31/2017 | 5,693 | 253 | N/A | 503 | N/A |
9/30/2017 | 5,224 | 176 | N/A | 375 | N/A |
6/30/2017 | 5,122 | 348 | N/A | 455 | N/A |
3/31/2017 | 5,159 | 409 | N/A | 535 | N/A |
12/31/2016 | 5,279 | 450 | N/A | 336 | N/A |
9/30/2016 | 5,089 | 378 | N/A | 381 | N/A |
6/30/2016 | 4,994 | 219 | N/A | 210 | N/A |
3/31/2016 | 4,757 | 255 | N/A | 17 | N/A |
12/31/2015 | 4,497 | 162 | N/A | 107 | N/A |
9/30/2015 | 4,505 | 62 | N/A | 253 | N/A |
6/30/2015 | 4,434 | 93 | N/A | 391 | N/A |
3/31/2015 | 4,644 | 47 | N/A | 475 | N/A |
12/31/2014 | 4,832 | 170 | N/A | 550 | N/A |
9/30/2014 | 4,843 | 326 | N/A | 595 | N/A |
6/30/2014 | 4,860 | 306 | N/A | 539 | N/A |
3/31/2014 | 4,887 | 365 | N/A | 597 | N/A |
12/31/2013 | 4,933 | 452 | N/A | 655 | N/A |
9/30/2013 | 5,074 | 550 | N/A | 622 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 600216's forecast earnings growth (25.1% per year) is above the savings rate (2.9%).
Earnings vs Market: 600216's earnings (25.1% per year) are forecast to grow faster than the CN market (21.8% per year).
High Growth Earnings: 600216's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 600216's revenue (9.9% per year) is forecast to grow slower than the CN market (13.4% per year).
High Growth Revenue: 600216's revenue (9.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 600216's Return on Equity is forecast to be low in 3 years time (8.7%).